Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer

Locoregional Recurrence ◽

Breast Conservation ◽

Growth Factor Receptor ◽

Breast Conservation Therapy ◽

Adjuvant Trastuzumab ◽

Node Negative ◽

Epidermal Growth ◽

Adjuvant Trastuzumab Reduces Locoregional Recurrence in Women Who Receive Breast-Conservation Therapy for Lymph Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Breast Diseases A Year Book Quarterly ◽

10.1016/j.breastdis.2012.10.004 ◽

2012 ◽

Vol 23 (4) ◽

pp. 381-382

Author(s):

S. Register ◽

J.L. Wright

Keyword(s):

Breast Cancer ◽

Locoregional Recurrence ◽

Breast Conservation ◽

Growth Factor Receptor ◽

Breast Conservation Therapy ◽

Adjuvant Trastuzumab ◽

Node Negative ◽

Epidermal Growth ◽

The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy

Breast Diseases A Year Book Quarterly ◽

10.1016/j.breastdis.2016.04.004 ◽

2016 ◽

Vol 27 (2) ◽

pp. 160-161

Author(s):

R. Gopal

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Locoregional Recurrence ◽

Growth Factor Receptor ◽

Adjuvant Trastuzumab ◽

Epidermal Growth ◽

Adjuvant Trastuzumab Reduces Locoregional Recurrence in Women who Undergo Breast Conservation Therapy for Node-Negative HER2-Positive Breast Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2010.07.257 ◽

2010 ◽

Vol 78 (3) ◽

pp. S98

Author(s):

A.P. Kiess ◽

H.L. McArthur ◽

K. Mahoney ◽

S. Patil ◽

P.G. Morris ◽

...

Keyword(s):

Breast Cancer ◽

Locoregional Recurrence ◽

Breast Conservation ◽

Breast Conservation Therapy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Node Negative ◽

Her2 Positive Breast Cancer ◽

The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy

Annals of Surgical Oncology ◽

10.1245/s10434-014-4321-2 ◽

2015 ◽

Vol 22 (8) ◽

pp. 2517-2525 ◽

Cited By ~ 20

Author(s):

Ryan M. Lanning ◽

Monica Morrow ◽

Nadeem Riaz ◽

Heather L. McArthur ◽

Chau Dang ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Locoregional Recurrence ◽

Growth Factor Receptor ◽

Adjuvant Trastuzumab ◽

Epidermal Growth ◽

Combination Trastuzumab and Chemotherapy May Have a Role in Women With Small, Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2014.58.2965 ◽

2015 ◽

Vol 33 (1) ◽

pp. 124-125 ◽

Cited By ~ 1

Author(s):

Heather L. McArthur ◽

Patrick G. Morris ◽

Clifford A. Hudis

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Node Negative ◽

Epidermal Growth ◽

Abstract PS10-52: Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

10.1158/1538-7445.sabcs20-ps10-52 ◽

2021 ◽

Author(s):

Omer Diker ◽

Burak Yasin Aktas ◽

Recep Ak ◽

Bahadir Koylu ◽

Onur Bas ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Life Experience ◽

Real Life ◽

Growth Factor Receptor ◽

Node Negative ◽

Epidermal Growth ◽

Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer

npj Precision Oncology ◽

10.1038/s41698-020-00128-1 ◽

2020 ◽

Vol 4 (1) ◽

Author(s):

Ke-Da Yu ◽

Xin Wang ◽

Wan-Kun Chen ◽

Lei Fan ◽

Miao Mo ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Adjuvant Trastuzumab ◽

Epidermal Growth ◽

Faculty Opinions recommendation of Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735447541.793581150 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Node Negative ◽

Epidermal Growth ◽

Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Escalation or De-Escalation?

Journal of Clinical Oncology ◽

10.1200/jco.21.01716 ◽

2021 ◽

pp. JCO.21.01716

Author(s):

Maho Tanaka ◽

Akihiko Shimomura ◽

Hiroyuki Terakado ◽

Chikako Shimizu

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Adjuvant Treatment ◽

Growth Factor Receptor ◽

Node Negative ◽

Epidermal Growth ◽

High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab

Cancer Management and Research ◽

10.2147/cmar.s231444 ◽

2020 ◽

Vol Volume 12 ◽

pp. 475-484 ◽

Cited By ~ 1

Author(s):

Li Jiang ◽

Jianjiang Fang ◽

Jinhua Ding

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Poor Survival ◽

Adjuvant Trastuzumab ◽

Epidermal Growth ◽